Zuellig Pharma
Zuellig Pharma, a leading healthcare services provider, is headquartered in Singapore and operates extensively across Asia. Founded in 1922, the company has established itself as a key player in the pharmaceutical distribution and healthcare solutions industry, serving markets in over 13 countries, including China, Malaysia, and the Philippines. Specialising in supply chain management, logistics, and market access services, Zuellig Pharma is renowned for its innovative approach to healthcare delivery. The company’s unique offerings include advanced temperature-controlled logistics and digital health solutions, which enhance patient access to essential medicines. With a strong market position, Zuellig Pharma has achieved numerous milestones, including partnerships with major pharmaceutical companies and recognition for its commitment to improving healthcare outcomes in the region. Its dedication to quality and efficiency continues to set it apart in the competitive landscape of healthcare services.
DitchCarbon Score
How does Zuellig Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zuellig Pharma's score of 55 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zuellig Pharma's reported carbon emissions
In 2023, Zuellig Pharma reported total carbon emissions of approximately 285,822,000 kg CO2e. This figure includes 10,640,000 kg CO2e from Scope 1 emissions, 27,683,000 kg CO2e from Scope 2 emissions (market-based), and a significant 247,499,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions encompass various categories, with upstream transportation and distribution contributing the largest share at about 136,648,000 kg CO2e. Comparatively, in 2022, the total emissions were approximately 309,279,000 kg CO2e, indicating a reduction in emissions year-on-year. The company has set ambitious targets to further decrease its carbon footprint, committing to a 42% reduction in absolute Scope 1 and 2 GHG emissions by 2030, using 2021 as the base year. Additionally, Zuellig Pharma aims for a 25% reduction in absolute Scope 3 emissions from specific categories, including fuel and energy-related activities, upstream transportation and distribution, and waste generated in operations, also by 2030. Zuellig Pharma's emissions data is cascaded from its parent company, Zuellig Pharma Holdings, reflecting a corporate commitment to sustainability. The company actively discloses its emissions across all three scopes, demonstrating transparency and accountability in its climate initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 9,551,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 54,061,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 341,689,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zuellig Pharma is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
